| Literature DB >> 22140446 |
Parya Saberi1, Mallory O Johnson.
Abstract
BACKGROUND: As HIV infection has shifted to a chronic condition, self-care practices have emerged as an important topic for HIV-positive individuals in maintaining an optimal level of health. Self-care refers to activities that patients undertake to maintain and improve health, such as strategies to achieve and maintain high levels of antiretroviral adherence. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2011 PMID: 22140446 PMCID: PMC3227571 DOI: 10.1371/journal.pone.0027533
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Selection process for study inclusion.
Summary of quantitative studies with primary outcomes.
| Source | Country, City/StateStart-End YearSample sizeAge (years)% Male% MSM% BL% WH | Inclusion / Exclusion Criteria | Study Objectives | If examined interventions, description of intervention | Length of follow-up | Outcomes | |||
| Method of Adherence Assessment: IntervalAdherence Outcomes | Viral load (copies/mL) | CD4+ cell count (cells/mm3) | Other Outcomes | ||||||
| Andrade et al, 2005 | United States, Maryland1999–2000N = 58Mean age = 3859%N/R88%N/R | Inclusion: ≥18 years, able to self-medicate, care at Johns Hopkins Moore HIV Clinic, treatment-naïve & initiating ARV or treatment-experienced & switching ARV (had ≤3 prior ARV regimens)Exclusion: inability to self-medicate, severe dementia, institutionalization | Assess if use of Disease Management Assistance System (DMAS: programmable medication reminder device providing verbal reminders at ARV dosing times) device improves ARV adherence, viral load, and CD4+. | Control: Monthly individualized 30-minute adherence counseling session+standardized adherence feedback transcript (education on barriers of adherence & hazards of non-adherence)Intervention: Same as controls+DMAS | 24 weeks | - EDM & self-report: 4 days- Overall mean adherence by electronic drug-exposure monitoring caps: 80% in DMAS vs 65% in control (NS) | - Undetectable viral load: 34% in DMAS vs 38% in controls (p = 0.49)- 1log10 reduction: 72% in DMAS vs 41% in controls (p = 0.02)- Mean reduction: −2.1log10 DMAS vs −0.98log10 controls (p = 0.02) | Mean CD4+: 301+/−172 DMAS vs 250+/−172 controls (p = 0.28) | Post-hoc analysis:- Mean adherence in memory impaired (n = 31): 77% DMAS vs 57% controls (p = 0.001)- Mean adherence in memory intact: 83% DMAS vs 77% controls (p = 0.25)QOL: controls had improved & DMAS had reduced QOL score. |
| Fairley et al, 2003 | Australia, Melbourne2001–2002N = 43Mean age = 3898%91%N/RN/R | Inclusion: ≥18 years, not planning to interrupt or change ARVs in next 3 month, had missed at least 1 dose of treatment by self-report in last month | Determine if a comprehensive adherence package improved self-reported ARV adherence pre- and post-intervention. | Use of adherence package: an educational program (on HIV, HIV treatment, importance of adherence), medication planner, & choice of adherence aids (pillbox, text messaging at scheduled doses, or medication alarm). | 5 months | - Self-report: 4, 7, 28 days- Missed doses decreased in last 4 days (0.76 to 0.38, p = 0.03) & last 7 days (1.5 to 0.74, p = 0.005), but not last 28 days (2.5 to 2.5, p = 0.63)- Morisky score: pre- intervention = 2.9, post- intervention = 3.3 (p = 0.006) | Undetectable viral load: 73% pre-intervention vs 74% post-intervention (p = 1.0) | Mean CD4+: 513 pre-intervention vs 551 post-intervention (p = 0.8) | Report of use: 17 began timed pillbox, 13 used plain pillbox, 11 SMS text, 6 declined aids |
| Golin et al, 2002 | United States, North Carolina1998–1999N = 117Mean age = 3880%N/R26%16% | Inclusion: English/ Spanish speaking, newly initiating PIs or NNRTIs | Examine relationship between adherence & patient factors, regimen factors (adherence aids such as medication lists, timers, & pillboxes), clinical interaction, & social factors. | None | 48 weeks | - MEMS, pill count, self-report: 4 weeks- Adherence in those using no adherence aids = 67.5% vs adherence = 76% among top quartile of adherence aid users (p = 0.01) | |||
| Iroha et al, 2010 | Nigeria, Lagos2008N = 21243%: 60–119months48.1%N/RN/RN/R | Inclusion: Caregivers of children who had been on ARVs for at least 30 days & who consented to participate | Determine level of ARV adherence among pediatric patients & barriers & facilitators of adherence according to caregivers. | None | None | - Self-report: 3 days- Use of reminders not associated with adherence- 30% of those adherent used reminders vs 31% of those non-adherent | |||
| Kalichman et al, 2005 | United States, GeorgiaN/RN = 446Mean age = 40.684%56%77%19% | Inclusion: Use of internet at least once monthly in past 3 months | Examine Internet use in HIV+ adults, including use of Internet for health, social support, & non-health/social support. Examine characteristics of those who use Internet for health-related information. | None | None | - Self-report: 7 days- 1.9 times odds (95% CI = 1.2–3.2) of missing medications in those not using Internet for health information vs those who did use Internet for health information | Odds of undetectable viral load for those who did not use Internet for health was 0.9 times (95% CI = 0.6–1.6) vs those who did use Internet for health | - CD4+ not associated with Internet use (adjusting for active coping & education)- CD4+ related to Internet use (adjusting for education) | |
| Kalichman et al, 2001 | United States, WisconsinN/RN = 112Median age = 380%0%88%9% | N/R | Compare information, motivation, behavioral skills, & use of specific ARV adherence strategies in HIV+ women who had missed ≥1 dose in past week to women who were adherent to ARVs in past week. | None | None | - Self-report: 7 days- Those who missed a dose more likely to have ever used pillboxes & datebooks- A trend in those who missed doses for greater past use of timers & beepers- No difference between groups for current use of strategies | Report of use: 33 of those who missed & 39 of those who adhered reported using adherence strategies such as timers, beepers, pill boxes, reminder notes, & date books | ||
| Levy et al, 2004 | Australia, Melbourne2002–2002N = 68Mean age = 4287%68%N/RN/R | Inclusion: ≥18 years,, obtained ARVs from the AlfredExclusion: Those planning on interrupting or changing treatment within next 3 months or those reporting 100% adherence with undetectable viral load | Determine the impact of education-based adherence intervention on adherence. | Adherence aids (pillboxes, electronic alarms) plus general HIV education plus individualized ARV counseling (given computerized medication planner) plus availability of pharmacist pager for urgent advice or adherence problems. | 20 weeks | - Self-report: 4, 7, 28 days- Decrease in missed doses: in last 4 days decrease from 1.9 to 1; in last 7 days decrease from 3 to 1.8, in last 28 days decrease from 7.4 to 4.2 (all p<0.001)- Improved Morisky score (1.3 to 0.5, p = 0.001) | Viral load: pre-intervention = 21,801, post-intervention = 17,264 (p = 0.39) | - CD4+: pre-intervention = 382, post-intervention = 406 (p = 0.70)- CD4%: pre = 20%, post = 19.5% (p = 0.83) | |
| Lyon et al, 2003 | United States, Washington1998–2000N = 23Age range = 15–2334.8%N/R100%0% | N/R | Develop a pilot program to increase ARV adherence among HIV+ youth & involve families & peers in this effort (where youth asked to identify adult family member or adult friend who could act as their treatment buddy). | Biweekly group meetings to discuss topics (e.g., purpose of ARV therapy, managing AEs, provider communication, etc), +education session for youth & family separately, +joined interactive review using game show format. On alternative weeks, only youth met to discuss medications & adherence devices (pillboxes, beepers, calendars, wrist watches with alarms). | 12 weeks | - Self-report: 2 weeks- Increased ARV adherence between study start and end- Miss ≥1 dose yesterday: start = 50%, end = 12%- Miss ≥1 dose in past 2 days: start = 43%, end = 18%- Miss ≥1 dose in past 2 weeks: start = 78%, end = 36%- “forgot” as reason for missing: study start = 43%, study end = 40% (alarm watch did not seem effective even though rated as best of the 5 adherence aids) | 4 youths had viral load reduction to undetectable during group | At 6 months: 4 youth had improved CD4+ to >500 | Report of use: In qualitative interviews, caregivers thought that some interventions that would help youth with adherence would be: 1) videotapes featuring teens with HIV, 2) vibrating beepers that hold pills, 3) watches with alarm. |
| Mannheimer et al, 2006 | United States, 24 states1999–2003N = 928Mean age = 3878%N/R55%25% | Inclusion: ARV-naïveExclusion: sites already using interventions similar to the study for most patients | Assess efficacy of medication managers (MM) or alarms (ALR) in ARV-naïve HIV+ persons with virologic failure occurring on or after 4-month follow-up visit. | 2×2 factorial-Intervention:1) MM: individualized, structured, long-term adherence support from MM using IMB model2) ALR: individually programmed alarm3) MM+ALRControl: standard of care | 30 days (median) | - Self-report: 3 days- MM vs no-MM: higher rate of reporting 100% adherence (OR = 1.42, p<0.001)- ALR vs no-ALR: no significant difference for adherence | - MM vs no-MM: 13% lower rate of 1st virologic failure on or after 4 months (p = 0.13)- ALR vs no-ALR: rate of 1st virologic failure was 25% | - MM vs no-MM: higher mean increase in CD4+ from baseline (22.5 higher in MM, p = 0.01)- ALR vs no-ALR: no difference | QOL:MM vs no-MM: no significant differenceALR vs no-ALR: no significant difference |
| Murphy et al, 2002 | United States, CaliforniaN/RN = 79Mean age = 3988%N/R46%30% | Inclusion: ≥18 yrs, prescribed ARVs, English speaking, not participating in other medication adherence study or other clinical trial, no psychiatric conditions making patient unable to participate in group experience, having difficulty with medication adherence (missed doses once/week or more) | Test hypothesis that patients assigned to multidisciplinary & multicomponent intervention condition (using behavioral strategies, simplified patient information, & social support) are more likely to be adherent to ARVs than those in standard of care condition. | Intervention: 5 group (information on HIV treatment & adherence, modify/strengthen adherence plan, etc) & 2 individual sessions (identify barriers & adherence plan, gain control over health care, & communication with medical provider). Behavioral strategies consisted of pillboxes, wrist alarms, & beepers.Control: standard of care | 3 months | - Self-report: 3 days & 1 month- From immediate post-intervention to 3-month follow-up, a trend for intervention group to not taking doses any later than 1 hour of scheduled time vs controls (p = 0.06)- No difference in self reported adherence- Decline in use of behavioral strategies from baseline to 3 months in control group (p = 0.01) | |||
| Murphy et al, 2007 | United States, CaliforniaN/RN = 141Mean age = 39.982.4%N/R47.9%23.2% | Inclusion: ≥18 yrs, prescribed ARVs, ARV non-adherent (miss ≥1×/wk), English-speaking, receiving care at AIDS Healthcare Foundation, CD4+>100, no opportunistic infections 1 month prior to enrollment, not participating in other medication adherence or clinical trials, no psychiatric condition (schizophrenia, bipolar) | Test hypothesis that patients assigned to intervention condition (behavior change strategies, social support, & simplified patient education information) would be more likely to be adherent than those in standard of care. | Intervention: 5 sessions using behavioral strategies (simple reminder strategies, self-monitoring, medication preparation systems, etc) & cognitive-behavioral techniques (communication skills, etc), simplified HIV information, social support. 4 booster sessions to review intervention & patient experience, a jeopardy-like adherence game, & review of adherence barriers & problem-solving.Control: standard care | 9 months | - Self-report, pill count, MEMS: various intervals3 months: no difference for any adherence measure9 months: intervention MEMS adherence = 70% & pill-count = 78%; control MEMS adherence = 59% & pill-count = 69%From 3 to 9 months:- Intervention: increase % dose adherence (p = 0.05), marginal effect for % days adherence (p = 0.06), no change pill-count adherence- Control: no change dose adherence, decline % days adherence (p = 0.02), decline pill-count adherence (p<0.01) | |||
| Safren et al, 2003 | United States, MassachusettsN/RN = 70N/R80%67%30%N/R | Inclusion: Adherence <90% at 2 weeks & return for 2week assessment | Test feasibility, utility, & efficacy of customizable pager, programmed using web-based technology, to increase & maintain adherence in those with pre-existing adherence problems. | After 2 weeks of monitoring adherence, those with <90% adherence randomized:Intervention: receive a pagerControl: continue monitoring | 12 weeks | - MEMS: 2 & 12 weeks- Pager group had more adherence improvement vs controls (P<0.004)- Pager group: baseline 55% adherence, 70% at week 2 & 64% at week 12; control arm, had 57% adherence at baseline, 56% in week 2, & 52% at week 12 | |||
| Samet et al, 2005 | United States, Massachusetts1997–2000N = 151Mean age = 42.981%23.5%47%30% | Inclusion: current or lifetime history of alcohol problems (2 or more positive responses to CAGE screening questionnaire or clinical diagnosis), on ARV, English or Spanish fluency, Mini-Mental State Exam score ≥21, no plans to move from Boston in 2 years | Assess effectiveness of an individualized multi-component intervention (including watch with timer) to promote ARV adherence in a cohort of HIV+ individuals with history of alcohol problems. | Intervention: 4 encounters with RN to address alcohol problems, provide watch with programmable timer, enhance perception of treatment efficacy, & deliver individually tailored assistance to facilitate medication use (exploring ways to tailor medications)Control: standard of care | 13 months | - Self-report: 3 & 30 days- No statistically significant difference in adherence between intervention & control groups from baseline to 6 months or baseline to 12 months | No significant difference in viral load | - No significant difference in CD4+ | Subgroup analysis: No significant difference in primary or secondary outcomes in subgroups (gender, hazardous drinking, adherence ≥95%, IDU in past 6 months, viral load <500, CD4+ ≤350) |
| Samet et al, 1992 | United States, Massachusetts1990N = 83Median age = 3680%28%20%46% | Inclusion: ≥18 yrs, current ZDV use | Determine extent of & clinical variables (including timers) associated with ZDV adherence. | None | None | - Self-report: 1 & 7 days- Variable associated with >80% ZDV adherence was use of medication timer (OR = 4.4, 95% CI = 1.0–19.1)- Most common reasons for missing were “forgot…” (75%) & “did not have the medication with me” (43%) | |||
| Simoni et al, 2010 | China, Beijing2006–2008N = 70Mean age = 3681%N/RN/RN/R | Inclusion: Mandarin-speaking at Ditan Hospital, ≥18 yrs, CD4<350, eligible for ARV, willing to & physically capable of attending follow-up visits at the hospital.Exclusion: Cognitively impaired & actively psychotic | To evaluate the feasibility & initial efficacy of a nurse-delivered adherence intervention among HIV+ outpatients initiating ARVs in Beijing, China. | All received 1 educational session, daily medication schedule, pillbox, & referral to peer support group, then randomized:Intervention: choice of electronic reminder device (their cell phone or study reminder device), 3 counseling sessions alone or with adherence partner (formulating daily medication schedule, setting reminder strategies, etc), or both reminder & counseling.Control: standard of care | 25 weeks | - Self-report & EDM: 7 & 30 daysSelf-report: 100% adherence more likely at 13, 19, 25weeks in intervention armEDM: Intervention arm had greater dose & on-time adherence than control (NS)Longitudinal analysis: >2-fold increased odds of 100% adherence for intervention vs control for cumulative effect of average weekly improvements between 7 & 13 weeks (OR = 2.23, 95% CI = 1.05–4.72, p = 0.04) | - Both arm showed comparable improvement in viral load over time (NS).- No difference between arms in longitudinal analysis. | - No statistically significant difference between arms in CD4+ gain.- No difference between arms in longitudinal analysis. | Feasibility:- Minimal attrition.- Of 28 who opted for counseling, 75% completed 2 or 3 sessions.- 12 opted for counseling with treatment adherence partner (mainly spouse or partner).- 26 opted for alarm: 7 used own cell phone & remaining used study alarm without problem. |
| Simoni et al, 2009 | United States, Washington2003–2007N = 224Mean age = 4076%N/R30%47% | Inclusion: ≥18 yrs, proficient in English, living within service area of the pager, initiating or changing at least 2 ARVsExclusion: Cognitively impaired, actively psychotic, or known history of harming others | Determine relative efficacy of peer support & pager messaging strategies in improving med adherence & clinical outcomes among those initiating or switching to a new ARV regimen. | All met with pharmacist, nutritionist, case manager, then randomized:Intervention:1) Peer support: 6 twice monthly gatherings & weekly phone calls.2) Pager messaging: customized pager; 3 pages daily for 2 months, then tapered in last month; confirmation return page requested; messages included dose reminders; educational; adherence assessment; entertainment3) Both peer & pagerControl: standard of care | 9 months | - Self-report & EDM: 7 daysPeer vs no peer:- A 2-fold increased odds of 100% adherence between 2 weeks & 3 months (95% CI = 1.1–4.01, p = 0.02)- Finding did not persist after 6 & 9 monthsPager vs no pager:- Did not predict improved odds of 100% adherence at 3 or 9 months, but was marginally associated with | - No peer effect for viral load- No pager effect at any time point for viral load | - No peer effects for CD4+- No pager effect at any point for CD4+ | Post-hoc analysis:- Peer meetings did not predict adherence differences, but greater attendance associated with reduced viral load at 3, 6 & 9 months- Attendance marginally associated with CD4+ at 3months- More pager response predicted significant reduction in log10 viral load at 3 & 9 months- Pager response predicted significant increase in CD4+ at 3, 6, & 9 months |
ARV: antiretroviral; BL: Black/African-American; CI: confidence interval; DMAS: Disease Management Assistance System device; EDM: electronic drug monitoring; IMB model: Information, Motivation, Behavioral Skills model; IDU: injection drug use; MEMS: Medication Event Monitoring System (electronic drug monitoring); MSM: men who have sex with men; MM: medication managers; N/R: not reported; NS: not statistically significant; OR: odds ratio; QOL: quality of life; RN: registered nurse; SMS: short message service; vs: versus; WH: White; ZDV: Zidovudine.